Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer

Abstract EN

Lung cancer accounts for the majority of cancer-related deaths worldwide of which non-small-cell lung carcinoma alone takes a toll of around 85%.

Platinum-based therapy is the stronghold for lung cancer at present.

The discovery of various molecular alterations that underlie lung cancer has contributed to the development of specifically targeted therapies employing specific mutation inhibitors.

Targeted chemotherapy based on molecular profiling has shown great promise in lung cancer treatment.

Various molecular markers with predictive and prognostic significance in lung cancer have evolved as a result of advanced research.

Testing of EGFR and Kras mutations is now a common practice among community oncologists, and more recently, ALK rearrangements have been added to this group.

This paper discusses various predictive and prognostic markers that are being investigated and have shown significant relevance which can be exploited for targeted treatment in lung cancer.